A5102016891- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Chronic Lymphocytic Leukemia Research
- Autoimmune and Inflammatory Disorders Research
- Mesenchymal stem cell research
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Multiple Myeloma Research and Treatments
- Eosinophilic Disorders and Syndromes
- Radiomics and Machine Learning in Medical Imaging
- Antifungal resistance and susceptibility
- Blood Coagulation and Thrombosis Mechanisms
- Protein Degradation and Inhibitors
- Viral-associated cancers and disorders
- Neutropenia and Cancer Infections
- Platelet Disorders and Treatments
- CRISPR and Genetic Engineering
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- CNS Lymphoma Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
Zhengzhou University
2013-2025
Henan Cancer Hospital
2009-2025
First Affiliated Hospital of Zhengzhou University
2008-2024
Henan University
2012
Zhengzhou Central Hospital
2010
Objective: To analyze the treatment-free remission (TFR) outcomes after discontinuation of tyrosine kinase inhibitor (TKI) in children with chronic myeloid leukemia (CML). Methods: In this retrospective cohort study, clinical data 14 phase CML aged <18 years who had achieved stable deep molecular response (DMR) for ≥ 2 standardized treatment TKI and a strong desire to discontinue at Henan Cancer Hospital from September 30, 2016 January 2022 were collected retrospectively. According different...
Abstract Background The objective of this study was to assess patient‐reported outcomes (PROs), including health‐related quality life (HRQoL) and anxiety depression symptoms, identify associated variables in patients with tyrosine kinase inhibitor (TKI)‐resistant chronic myeloid leukemia (CML) chronic‐phase (CP) or accelerated‐phase (AP) who were receiving olverembatinib. Methods Patients multicenter studies invited complete the European Organization for Research Treatment Cancer...
Background: Simultaneous multiple myeloma (MM) and pulmonary adenocarcinoma is a rare occurrence, thus, treatment challenge. This study reports on 1 such case of MM with concurrent lung cancer, where an accurate diagnosis was made the patient underwent for both cancers. Case summary: A 68-year-old man presented 2 months progressive lower back pain. Visualization magnetic resonance imaging (MRI) revealed collapsed vertebrae from T12 to S3, as well altered signal intensity at T3 vertebra. The...
Philadelphia chromosome (Ph) is a hallmark of chronic myeloid leukemia (CML), which exists in more than 90% CML and 3% to 40% acute lymphoblastic (ALL).A 25-year-old man was diagnosed with phase. He first received treatment hydroxyurea, achieving hematological remission following imatinib mesylate for main treatment. A year later, he began appear unexplained high fever ineffective antibiotic bone morrow blood tests indicated blast crisis. Both BCR/ABL 210 190 fusion transcript were positive....
To evaluate the effectiveness of using a modified lung imaging reporting and data system (Lung-RADS) for risk stratification pure ground-glass nodules (pGGNs) in low-dose computed tomography (LDCT) cancer (LC) screenings China.Eight subjects with nine pGGNs originating from Cancer Screening Program were enrolled as training set 32 asymptomatic 35 selected validation November 2013 to October 2018. The complementary Lung-RADS categories based on GGN-vessel relationship (GVR). correlations...
Abstract Background In multiple myeloma (MM), impact of specific chromosomal translocations involving IgH (14q21 locus, including t(4;14), t(11;14), and t(14;16)) has been explored extensively. However, over 15% MM patients harboring translocation with undefined partners have long ignored. Methods A prospective non‐randomized cohort study a total 715 newly‐diagnosed cases was conducted, 13.6% whom were t(14;undefined) positive. The whole divided into four groups: no split (47.7%); (13.6%);...
X-linked lymphoproliferative syndrome type 1 (XLP1) is an recessive genetic disorder with a strong resemblance to hemophagocytic lymphohistiocytosis (HLH). Causative mutations for XLP1 have been identified in SH2D1A, located on chromosome Xq25. We report case of 18-month-old male novel nonsense mutation SH2D1A. The patient presented the typical phenotype HLH, including splenomegaly and hemophagocytosis bone marrow. Thus, he was initially diagnosed HLH based HLH-2004 guidelines....
Objective To explore the efficacy and safety of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for children with severe aplastic anaemia (SAA) Ⅱ. Methods The clinical data 19 SAA-Ⅱ receiving allo-HSCT from January 2003 to May 2015 were retrospectively analyzed, including 11 male 8 female, median age 9(2-14) years old.There 9 patients received human leukocyte antigen-matched sibling donor (MSD) allo-HSCT, 10 unrelated (URD) allo-HSCT.Conditioning regimen was...